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We investigated the influence of the activation state of 
integrin «5/31 on its dependence on the PHSRN synergy 
site for binding* to RGD in fibronectin. K562 and MV3 
cells lacked av/33 expression and adhered to fibronectin  
through a5pl. Mel57 cells adhered through av/33 and 
«5)31. A recombinant fibronectin polypeptide, contain­
ing five type III repeats from the central cell binding 
domain 3Fn6-*10, and a mutated polypeptide lacking the 
synergy site were equally effective in promoting Mel57 
adhesion. For K562 and MV3, the mutated polypeptide 
was not or poorly active compared to the control 
polypeptide. Expression of av/33 in MV3 induced strong 
adhesion to the m utated polypeptide. TS2/16 stimula­
tory /31-integrin antibodies or Mn2+ induced a5j31-medi- 
ated adhesion of K562 and MV3 to GRGDSP. In the pres­
ence of TS2/16 or Mn2+, a5/31-mediated MV3 adhesion to 
the m utated polypeptide was equally strong as adhesion 
to the control polypeptide. Mn2 f or TS2/16 induced weak 
K562 binding to the mutated polypeptide, and in the 
presence of a combination of phorbol 12-myristate 13- 
acetate, Mn2+, and TS2/16, a5/31-mediatedK562 adhesion 
to the m utated and control polypeptide was equally 
strong. Our findings demonstrate that requirement for 
the PHSRN synergy site for a5/31-mediated adhesion to 
RGD in fibronectin depends on the activation state of 
the integrin.
Fibronectin (Fn)1 is an extracellular matrix glycoprotein that 
functions in cell adhesion and migration in wound healing, 
embryonic development, and malignant transformation (1, 2), 
The Fn molecule is composed of three types of repeating mod­
ules, termed type I, II, and III repeats (3), which are organized 
into functional domains. Proteolytic cleavage yields several 
fragments containing domains that promote cell adhesion, in­
cluding the carboxyl-terminal HepII domain (4), the alterna­
tively spliced type III connecting segment (5), and the central 
cell binding domain (CCBD).
The CCBD consists of type III repeats, each containing ap­
proximately 90 amino acids (6). Cells bind to the CCBD via 
receptors of the integrin family (7). Integrins are a(3 het-
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1 The abbreviations used are; Fn, fibronectin; BSA, bovine serum 
albumin; CCBD, central cell binding domain; 3FnlO, 10th type III 
fibronectin repeat; mAb, monoclonal antibody; PMA, phorbol 12-myris­
tate 13-acetate; DMEM, Dulbecco’s modified Eagle’s medium.
erodimeric transmembrane molecules mediating cell-cell adhe­
sion and attachment of cells to the extracellular matrix (8). 
Integrins that bind the CCBD include a3pi (9), a5fil (10, 11), 
avj31 (12), av/33 (13), aIIb/33 (14, 15), and av/36 (16).
The Arg-Gly-Asp (RGD) sequence in the 10th type III repeat 
(3Fnl0) is the key attachment site for binding of these inte­
grals to the CCBD, as demonstrated by inhibition of cell adhe­
sion with synthetic RGD-containing peptides (17,18). Further­
more, two synergistic regions in the CCBD besides RGD have 
been identified that are required for cell adhesion through 
aIIb/33 (19) and a5/31 (20-23). For «5/31 binding to Fn, the 
synergy region in 3Fn9 is the most important of these two 
regions (21), and recently, a short amino acid sequence Pro- 
His-Ser-Arg-Asn (PHSRN) was identified in this repeat that 
synergistically enhances the cell adhesion promoting activity of 
the RGD sequence (24). This sequence is also present in an 
11-amino acid integrin binding site from 3Fn9 that is recog­
nized by allbj33 (25).
Integrins do not always cons tit utively bind to their ligands 
with high affinity, Integrin adhesiveness can be stimulated by 
phorbol esters and other more physiologically relevant agonists 
(8, 26). In addition, antibodies have been described to integrin 
|31 (27-30), j32 (31), and /33 (32) subunits, which induce a high 
affinity state of the integrins. Studies with stimulatory /31 
antibodies on hematopoietic cells have demonstrated modula­
tion of binding to natural ligands (28-30), modulation of ligand 
specificity (33), modulation of binding to different regions in 
one ligand (34), and modulation of the minimal sequence of a 
binding site required for adhesion (35).
In the present study, we have investigated the role of the 
PHSRN synergy site in «5/31- and av/33-mediated cell adhesion 
to the CCBD in Fn. We show that requirement for the PHSRN 
synergy site for cell adhesion to the CCBD depends on the 
integrins expressed and on the activity of the integrins 
involved.
MATERIALS AND METHODS
Fibronectin, Fragmentst and Peptides—Plasma Fn was purchased 
from Sigma. A 120-kDa chymotryptic Fn fragment containing the 
CCBD (36, 37) was purchased from Life Technologies, Inc. Synthetic 
peptide Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) was obtained from the 
Department of Organic Chemistry, Faculty of Science, University of 
Nijmegen (The Netherlands) and covalently bound to bovine serum 
albumin (BSA) as previously described (38).
Production of Recombinant Fibronectin Polypeptides—To avoid the 
artifactual losses of adhesive activity known to result from adsorbing 
short polypeptides on substrates (e g . see Ref. 23), we used recombinant 
Fn polypeptides containing five type III Fn repeats from 3Fn6 through 
3FnlO. The 3Fn6-10 wild type expression construct was generated 
based on the T7 phage promotor and a Fn cDNA fragment encoding Fn 
type III repeat numbers 6-10 produced using the polymerase chain 
reaction method (24); the PHSRN sequence was present in repeat 9 and 
RGD in repeat 10 (Fig. 2A). The amino-terminal sequence of 3Fn6 
starts immediately after an initiation codon for methionine. To create
21612
Modulated Requirement for Fn Synergy Adhesion Site 21613
Table I
ins on K562, MV3
Mean fluorescence
C a3 a4 «5 (XV a l lb PI av/33
K562 4 4 4 46 7 3 52 3
MV3 4 69 31 62 13 3 107 2
Mel57 3 41 17 23 33 3 33 41
substitution mutants, two complementary oligonucleotides with appro­
priate sequences were synthesized, annealed, and then cloned between 
the BarriKI and EcoRl sites of 3Fn9. This yielded a mutated polypeptide 
3Fn6- 10(SPSDN) where the PHSRN sequence from 3Fn9 was substi­
tuted by SPSDN from 3Fn8 (Fig, 2, A  and B),
Protein expression was induced by 1 mM isopropyl-l-thio-/3-D-galac- 
topyranoside treatment of Escherichia coli strain BL21 (DE3, pLysS) 
containing the expression plasmid. The expressed recombinant 
polypeptides were purified by sequential DEAE and hydroxyapatite 
column chromatography. The polypeptide was eluted from a DEAE 
column (DE52, Whatman) using a linear gradient of 0-0,5 M NaCl in 10 
mM sodium phosphate (pH 7.4), 1 mM EDTA, 0.02% sodium azide, 
applied to a hydroxyapatite column (Bio-Rad), and eluted using a linear 
gradient from 5 m M  sodium phosphate (pH 6.5), 0.4 mM EDTA, 0.02% 
sodium azide to 250 mM sodium phosphate (pH 6.5), 0.4 mM EDTA, 
0.02% sodium azide. The fractions with peak absorbance were evalu­
ated for purity by SDS-polyacrylamide gel electrophoresis, pooled, dia- 
lyzed against phosphate-buffered saline without Ca2+ or Mg^+ and with 
0.02% sodium azide, and stored at -8 0  °C.
Cell Lines and Culture Conditions —The human melanoma cell lines 
used included Mel57 (39) and MV3 (40). The K562 erythroleukemic cell 
line was provided by Dr. Nancy Hogg. All cell lines were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Flow, Irvine, United 
Kingdom) supplemented with 10% fetal calf serum, penicillin, and 
streptomycin.
Antibodies—Anti-integrin antibodies included P1B5 anti-a3 (41), 
purchased from Telios Pharmaceuticals Inc. (San Diego); HP2/1 anti-a4 
(42), provided by Dr. Francisco Sanchez-Madrid; NKI-Saml anti-a5 
(30), provided by Dr. Carl Figdor; 4B4 anti-/31 (43), purchased from 
Coulter Immunology (Hialeah, FL); AJ2 anti-j31 (44), provided by Dr. 
Eberhard Klein; C17 anti-/33 (45), provided by Dr. Arnoud Sonnenberg; 
A109 polyclonal anti-av (46), purchased from Life Technologies, Inc.; 
10E5 anti-allb (47), provided by Dr. Barry Coller; and LM142 anti-av 
and LM609 anti-av/33 (48), provided by Dr. David Cheresh. The stim­
ulatory anti-integrin /31 mAbs were 8A2 (29), provided by Dr, Nicholas 
Kovach, and TS2/16 (49), provided by Dr. Francisco Sanchez-Madrid.
Cell Adhesion—Cell adhesion assays were performed as previously 
described (50). In short, polystyrene microtiter plates (Greiner, Alphen 
a/d Rijn, The Netherlands) were coated overnight with the appropriate 
adhesive ligands and blocked for 1 h at 37 °C with DMEM containing 
0.5% (w/v) BSA. Subsequently, 1 X 104 51Cr-labeled cells in 50 jud of 
DMEM/BSA were added to the wells and incubated for 30 min at 37 °C 
in 5% C02. Unbound cells were removed by washing with DMEM/BSA, 
bound cells were lysed by detergent, and radioactivity of the lysate was 
measured in a gamma counter. Results are presented as the mean 
percentage of cell binding from triplicate wells. For induction of adhe­
sion, radiolabeled cells were preincubated with TS2/16 or 8A2 mAbs for 
30 min at 4 °C before seeding in the wells or 1 mM MnCl2; or, 100 ng/ml 
phorbol 12-myristate 13-acetate (PMA) was added to the cells prior to 
seeding in the wells. For antibody inhibition studies, cells were prein­
cubated with the appropriate mAbs for 30 min at 4 °C before seeding 
into the wells.
Flow Cytometry-'Cells were incubated with mAbs in phosphate- 
buffered saline containing 0.5% (w/v) BSA and 0.02% (w/v) sodium 
azide for 30 min at 4 °C, After washing with phosphate-buffered saline/ 
BSA/azide, the cells were incubated with fluoréscein-isothyocyanate- 
labeled F(ab ')2 fragments of rabbit anti-mouse Ig antibodies (Dako, 
Glostrup, Denmark) for 30 min at 4 °C. After washing, fluorescence was 
measured on an Epics Elite flow cytometer (Coulter, Mijdrecht, The 
Netherlands).
Transfection—The full-length cDNA for the integrin /33 subunit (51), 
a kind gift from Dr. Erkki Ruoslahti, was cloned in the poly linker of the 
mammalian expression vector pBJlneo (52), kindly provided by Dr. 
René de Waal-Malefijt. 20 ¡±g of this construct was used for stable 
transfection of MV3 cells according to the calcium phosphate precipita­
tion method (53), using the calcium phosphate transfection system (Life 
Technologies, Inc.). After 48 h, stably transfected cells were selected by 
culturing in the presence of 1 mg/ml G418 (Life Technologies, Inc.) for
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F ig . 1. Inhibition of adhesion to Fnl20 kD a w ith  in teg rin  
mAbs. Cells were allowed to adhere to wells coated with 20 ¡xg/ml of a 
120-kDa fragment of Fn (Fnl20 kDa) in the absence (no) or in the 
presence of inhibitory mAbs to integrin subunits as indicated, Adhesion 
to BSA was less than 5%. One representative experiment of four is 
shown.
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F ig . 2. Recombinant FN polypeptides. A, schematic representa­
tion of a recombinant Fn polypeptide 3Fn6~10 consisting of five type III 
Fn repeats from 3Fn6 through 3FnlG and of a mutated Fn polypeptide 
3Fn6- 10(SPSDN) where the region containing PHSRN in 3Fn9 has 
been substituted by the corresponding region from 3Fn8 (hatched bar). 
B , in 3Fn6-10(SPSDN), 16 amino acid residues from 3Fn9 were sub­
stituted with the corresponding residues from 3Fn8 to disrupt the 
PHSRN site in 3Fn9. Boxed sequences are from 3Fn6-10(SPSDN). The 
region with italicized nucleotides differs from the original sequence in 
3Fn8 for technical reasons to alter restriction sites, but this does not 
alter the amino acid sequence.
2 weeks. Cell populations were enriched for av/33 expression by cell 
sorting in an Epics Elite flow cytometer using LM609 mAbs. After three 
cycles of sorting, transfected cell lines contained >95% av/33 positive 
cells. Cells were maintained in culture in medium containing 200 fig/ml 
G418 and were regularly monitored for av/33 expression.
RESULTS
K562> MV3, and Mel57 Differentially Adhere to the 
CCBD—Vfe investigated, adhesion of K562 human erythroleu- 
kemic cells and MV3 and Mel57 human melanoma cells to the 
CCBD. Of the integrins known to be involved in adhesion to Fn,
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K562 exclusively expressed «5/31 (Table I). MV3 and Mel57 
expressed «3/31, a4j31, and a5j31. In addition, Mel57 but not 
MV3 expressed av/33. MV3 and Mel57 expressed other av 
integrins including avj35 ( 54) and possibly av|31 that may bind 
to Fn,
To exclude influences from domains outside the CCBD that 
are known to have cell adhesive activity (HepII, IIICS), we used 
a 120-kDa Fn fragment that lacks the heparin-binding domain
and the V region but includes the CCBD. K562 adhered weakly 
to Fnl20 kDa, whereas MV3 and Mel57 both adhered strongly 
(Fig. 1). As expected from the surface expression data, adhesion 
of K562 was completely blocked by mAbs to a5 or pi. Even 
though MV3 expressed several Fn-binding integrins, adhesion 
was fully blocked by mAbs to a5, whereas mAbs to «3 or a4 or 
polyclonal anti-av had no effect. Adhesion of Mel57 was inhib­
ited approximately 35% by mAbs to a5 or /31 and about 50% by
K562 MV3 Me!57
(ug/ml) (ug/ml) (ug/ml)
F i g . 3. A dhesion to recom binant F n  polypeptides. K562, MV3, or Mel57 cells were allowed to adhere to wells coated with increasing 
concentrations of 3Fn6-10(SPSDN) (dotted line) or 3Fn6-10 {line) as indicated. Adhesion to 0.1 mg/ml BSA was less than 4%. One representative 
experiment of four is shown.
log. fluorescence
MV3neo MV3-/3 3
16 32 64 32 32
(ug/ml) (ug/ml)
Fig. 4, E xpression  of av/J3 on MV3 induces adhesion to 3Fn6—ÍO(SPSDN). A, MV3 cells were untransfected (dotted line), transfected with 
pBJlneo alone (thin line), or transfected with pBJlneo including integrin /33 cDNA followed by sorting with LM609 anti-av/33 mAbs (thick line). 
Shown is the relative fluorescence after incubation with LM609 and a fluorescein-isothyocyanate-labeled second antibody. jB, MV3neo or MV3-/33 
cells were allowed to adhere to wells coated with increasing concentrations of 3Fn6~10(SPSDN) (dotted line) or 3Fn6—10 {line) as indicated. Filled 
bars represent remaining adhesion to wells coated with 32 jug/ml 3Fn6-10(SPSDN) in the presence of inhibitory anti-integrin mAbs as indicated. 
Adhesion to BSA was less than 3%. One representative experiment of three is shown.
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mAbs to /33 or av/33 or by polyclonal av. The combination of 
mAbs to «5 and av/33 completely blocked adhesion of Mel57.
Thus, K562 adheres weakly to the CCBD through a5/31, MV3 
binds strongly through a5/31, and Mel57 binds strongly 
through «5/31 and av/33.
K562 and MV3 Require the PH SRN Synergy Site, Whereas 
for Mel57 RGD Is Sufficient—To study the mechanism of bind­
ing of these cells to the CCBD, we used a recombinant Fn 
polypeptide containing 3Fn6-3FnlO and a mutated polypep­
tide lacking the recently described PHSRN synergy site (24) 
(Fig. 2). As shown in Fig. 3, K562 did not adhere to the mutated 
polypeptide and weakly to the control polypeptide. Only very 
low adhesion of MV3 cells was observed to the mutated 
polypeptide, whereas adhesion of MV3 to the control polypep­
tide was five times higher. In contrast, Mel57 cells adhered 
strongly to both polypeptides. To investigate if this difference 
was due to differential expression of av/33, we transfected MV3 
cells with j33 cDNA, resulting in av/33 surface expression (Fig. 
4A), and used these cells in adhesion assays. Expression of 
av/33 provided MV3 cells with the capacity to adhere to 
GRGDSP (not shown) and to the mutated polypeptide, and this 
adhesion could be inhibited by C17 anti-/33 mAbs (Fig. 4B). A 
similar level of inhibition was found with LM609 anti-av/33 
(not shown).
From these results, we conclude that the differential require­
ment for the PHSRN synergy site for adhesion to RGD in the 
CCBD of MV3 versus Mel57 is due to the different binding 
mechanisms of a5/31 versus av/33.
Stimulation of <x5pl-mediated RGB Binding with /3i mAbss 
PM A, and Manganese—The fact that K562 did not adhere to 
the mutated polypeptide whereas MV3 did to a low extent (Fig.
3), even though both cell lines used 0:5)31, suggested that bind­
ing of «5/31 to RGD in 3FnlO might depend on the activation 
state of the integrin. To investigate this, we treated both cell 
lines with 8A2 and TS2/16 stimulatory j31 mAbs, with Mn2+, or 
with PMA prior to using them in adhesion assays to a GRGDSP 
peptide. PMA had no effect, 8A2 and TS2/16 induced weak 
adhesion of K562 to GRGDSP, and treatment of MV3 cells with 
these mAbs resulted in 25% adhesion to GRGDSP (Fig. 5A). A 
control /31-integrin mAb AJ2 had no effect (not shown). The 
strong binding of Mel57 was not enhanced by 8A2 or TS2/16. 
Mn2+ was less effective for K562 but induced adhesion of MV3 
cells up to 35%. We performed adhesion inhibition assays to 
examine whether the effect of 8A2 and TS2/16 was due to 
activation of ct5/31 or to the recruitment of other integrins. 
Induced adhesion of K562 to GRGDSP in the presence of 8A2 
(Fig. 5B) or TS2/16 (not shown) was blocked by mAbs to a5 and 
not by any of the other mAbs. In addition, even though 8A2 and 
TS2/16 may activate a3j31, «4/31, «5/31, and possibly av/31 on 
MV3 cells, induced adhesion of MV3 to GRGDSP was com­
pletely blocked by mAbs to «5, whereas mAbs to «3, «4, and av 
had no effect (Fig. 5B), The fact that the 4B4 anti-jSl mAb did 
not inhibit adhesion in the presence of 8A2 is in line with the 
report that activating and inhibiting antibodies share a com­
mon epitope on the j31 subunit (55).
Thus, the strength of «5/31 binding to RGD can be increased 
by Mn2'1' and by activating /31 antibodies.
Requirement for the PH SRN Synergy Site Depends on the 
Activation State o f a5/3i —As stimulatory /31 mAbs and Mn2+ 
induced a5/31~mediated adhesion to GRGDSP, we hypothesized 
that the activation state of «5/31 determines the requirement 
for the PHSRN synergy site for cell adhesion to the CCBD. 
Therefore, we treated K562 and MV3 cells with PMA, TS2/16, 
or Mn2+ and allowed them to adhere to the mutated and 
control Fn polypeptides. TS2/16 and, to a lesser extent, Mn2+ 
induced adhesion of K562 cells to the mutated polypeptide and
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F ig . 5. Stimulation of a501-mediated adhesion to  GRGDSP. A,
Cells were incubated in the absence (no) or in the presence of PMA, 8A2 
or TS2/16 stimulatory /31 mAbs, or manganese (Mn) and allowed to 
adhere to wells coated with 20 /xg/ml BSA-GRGDSP. B, cells that had 
been previously incubated in the absence (x) or in the presence of 8A2 
stimulatory /31 mAbs (8A2) were incubated in the absence {no) or in the 
presence of inhibitory anti-integrin mAbs as indicated and allowed to 
adhere to wells coated with 20 /xg/ml BSA-GRGDSP. Adhesion to BSA 
was less than 5%. One representative experiment of three is shown.
enhanced adhesion to the control polypeptide (Fig. 6). PMA 
enhanced adhesion of K562 cells to the control polypeptide but 
had no effect on adhesion to the mutated polypeptide. For MV3 
cells, no effect of PMA was observed, but the low adhesion to 
the mutated polypeptide was enhanced 5-fold by TS2/16 and 
Mn2+, resulting in a level of adhesion that was similar to that 
observed with the fully active control polypeptide,
The fact that in the presence of TS2/16 or Mn2+ no difference 
was observed between the mutated and control polypeptide 
regarding adhesion of MV3 cells, whereas for K562 the mu­
tated polypeptide was still poorly active, could suggest 1) that 
stimulation of MV3 cells resulted in recruitment of other RGD- 
binding integrins or 2) that «5/31 on K562 cells was not maxi­
mally activated by these agents. To exclude possibility 1, we 
used mAbs to «3, a4, «5, av, J31, /33, av/33, or the combination 
of these mAbs in the absence of anti-a5 for inhibition of TS2/ 
16-stimulated adhesion of MV3 cells to the mutated polypep-
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Pig. 6. S tim u la tion  o f adhesion  to  
reco m b in an t F n  po lypeptides. Cells 
were incubated in the absence (¡11) or in 
the presence of PMA (*), TS2/16 (A), or 
manganese (▼) and allowed to adhere to 
wells coated with increasing concentra­
tions of 3Fn6-10(SPSDN) (dotted line) or 
3Fn6~10 (line) as indicated. Adhesion to 
BSA was less then 4%. One experiment of 
three is shown.
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tide. Stimulated adhesion was blocked by the anti-aS mAb and 
not by any of the other mAbs or their combination (Fig. 7), 
suggesting that induction of adhesion to the mutated polypep­
tide of MV3 by TS2/16 was due to activation of ar5/31 and not to 
recruitment of other integrins.
To investigate possibility 2, we incubated K562 cells with 
PMA, TS2/16, or Mn2+ and the various combinations and al­
lowed the cells to adhere to the mutated and control polypep­
tide. In the presence of the combination of TS2/16 and Mn2+, 
adhesion to the mutated polypeptide was more than half the 
level of adhesion to the control polypeptide (Fig. 8). PMA had 
no effect by itself on adhesion to the mutated polypeptide but 
enhanced adhesion to the control polypeptide more than 2-fold. 
Finally, in the presence of the combination of PMA, TS2/16, 
and Mn2+, the control and the mutated polypeptide were 
equally effective in promoting adhesion of K562 cells. This 
adhesion was blocked by «5 mAbs (not shown).
From these results, we conclude that requirement of the 
PHSRN synergy site for a5/31-mediated adhesion to RGD in the 
CCBD depends on the activation state of «5/31.
DISCUSSION
In line with earlier reports, w e find that av/33 does not 
require the PHSRN site. We base th is  conclusion on 2 obser­
vations. First, Mel57 cells express avf33 and adhere equally 
well to all molecules tested containing RGD, i.e. GRGDSP, 
the mutated polypeptide lacking the synergy site 3F n6- 
lO(SPSDN), the control polypeptide 3Fn6-10, and Fnl20 kDa. 
Second, the av/33 negative MV3 cells do not adhere to RGD- 
containing ligands that lack the PH SR N  site, and transfection 
with j33 cDNA resulting in avj33 surface expression leads to 
binding of these cells to GRGDSP and 3Fn6-10(SPSDN),
These findings confirm and extend the observations that 
av/33 can be retained on an RGD column (56) whereas a5/31 
cannot (11). Furthermore, these data are in agreement with the 
recent report that av- and aS- but n ot <x5-containing integrins 
are bound by a column containing a  Fn fragment lacking the 
synergy region (57). Similarly, it has been reported that <*IIb/33 
but not av/33 binding to Fn can be inhibited by an 11-amino 
acid peptide from 3Fn9 that also contains the PHSRN sequence 
(25). Thus, RGD is sufficient for binding to Fn through avfi3,
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F i g . 7. Inhibition of stim ulated adhesion of MV3 to 3Fn6- 
lO(SPSDN) with integrin mAbs. MV3 cells were incubated in the 
absence or in the presence of TS2/16 and allowed to adhere to wells 
coated with 32 jug/ml 3Fn6-10(SPSDN). Inhibitory mAbs to integrin 
subunits were added as indicated. Adhesion to BSA was less then 3%. 
One experiment of three is shown.
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Fig. 8. Stimulation of adhesion of K562 to recombinant Fn 
polypeptides. K562 cells were incubated in the absence or in the 
presence of various combinations of PMA, TS2/16, and Mn2+ as indi­
cated and allowed to adhere to wells coated with 32 /xg/ml 3Fn6- 
lO(SPSDN) (dotted bars) or 3Fn6-10 {filled bars). Adhesion to BSA was 
less then 4%. One experiment of three is shown.
whereas a5/31 and aIIb/33 require the synergy region for effi­
cient binding to Fn (24, 25).
Parenthetically, it has been reported that cross-talk between 
av/33 and a5jSl can occur (58, 59). Therefore, the induced ad­
hesion to 3Fn6-10(SPSDN) upon expression of av/33 in MV3 
cells did not necessarily have to be due to avj33-mediated ad­
hesion. Even though Blystone et aL (59) show that av/33 regu­
lates only a5/31-mediated phagocytosis, in our system av/33 
might influence a5/31-mediated adhesion. Ligation of av/33 
with LM609 mAbs might induce a signal that inhibits a5/31. To 
exclude this possibility, we used C17 anti-/33 for adhesion in­
hibition assays. The fact that these mAbs inhibit adhesion of 
/33-transfected MV3 cells to 3Fn6-10(SPSDN) suggests that 
direct binding through av/33 rather than signaling to a5/31 is 
involved.
The major conclusion from this study is that the requirement 
for the PHSRN synergy site for a5/31-mediated adhesion to the 
CCBD depends on the activation state of a5/31. This is based on 
three findings. First, stimulation of K562 cells that express 
only a5/31, with Mn2+ or stimulatory j31-integrin mAbs, in­
duces adhesion to GRGDSP and 3Fn6-~10(SPSDN). Second, in 
the presence of the combination of PMA, TS2/16, and Mn2+, the 
mutated and control polypeptide are equally effective in pro­
moting K562 cell adhesion. Third, treatment of MV3 cells with 
these agents induces adhesion to GRGDSP and enhances ad­
hesion to 3Fn6~10(SPSDN) to the level of adhesion to 3Fn6-
10, and this effect is completely blocked by antibodies to a5 but 
not by mAbs to a3, a4, or av or the combination.
Even though the av/33-negative K562 and MV3 cells express 
similar levels of a5£l, they differ dramatically in binding to 
Fnl20 kDa through this receptor. The view of cell type-specific 
regulation of a5/31 affinity proposed by O’Toole et al. (60) sug­
gests that the default low affinity state of the integrin as 
observed in K562 is switched to a high affinity state in MV3. As 
a result, MV3 but not K562 cells bind strongly to Fnl20 kDa. 
Our finding that K562 cells bind poorly to Fn 120 kDa and that 
8A2 increases that adhesion two to three times is in line with 
earlier findings (61). As expected, Mn2+ and stimulatory /31 
mAbs do not affect the strong adhesion of MV3 to Fnl20 kDa. 
However, our findings demonstrate that these agents do in fact 
alter the avidity of a5/31 in MV3 cells but that this change can 
only be observed in the absence of the PHSRN synergy site. 
One interpretation of these findings is that intracellular factors 
(induced by PMA for K562 and factors already present in MV3) 
can increase the affinity of a5/31 to a level that RGD is recog­
nized in the Fn molecule and that additional extracellular 
events are required for the final activation of a5/31, leading to 
full adhesion to RGD in Fn. The synergy site could be involved 
in the last step by locking the RGD site in the «5/31 binding 
pocket, and in the presence of TS2/16 or Mn2+ that last step 
seems to be no longer required. Our finding that PMA enhances 
K562 adhesion to the control polypeptide, whereas by itself it 
has no effect on adhesion to the mutated polypeptide, is in line 
with this idea. Furthermore, the fact that K562 cells in the 
presence of TS2/16 bind strongly to the control polypeptide 
without the need for PMA demonstrates that optimal extracel­
lular stimulation (the synergy site plus stimulatory /31 mAbs) 
can abbrogate the need for intracellular activation (PMA).
It is of interest that comparable observations have been 
reported for a4/31 (35). Even though Jurkat and Ramos cells 
express an active form of a4/31 in the sense that they are 
capable of binding to the CS1 domain of Fn, they only bind to a 
peptide containing the EILDV recognition sequence from CS1 
in the presence of stimulatory /31 mAbs. The authors suggest 
that sequences may be present in the NH2-terminal portion of 
CS1 that strengthen a4/31 binding to EILDV, although none 
have yet been identified. Thus, the presence of sites that syn­
ergistic ally enhance binding of integrins to their recognition 
sequence might be a general mechanism, and activation by 
stimulatory /31 mAbs and Mn2+ may bypass the dependence on 
such sites. Our report, however, provides the first example of 
substitution of the function of a well characterized synergy site 
by agents that activate the integrins involved.
For leukocytes, stimulatory /3l mAbs also increase the affin­
ity of a4/31 for CS1 (35, 62) and for VCAM-1 (29), and they can 
even induce a4/31 binding to the RGDS sequence (34). MV3 
cells adhere to CS1 and tumor necrosis factor a-stimulated 
endothelial cells in the absence of stimuli (not shown), indicat­
ing the expression of active a4/31 on these cells. For MV3 cells 
in the absence or presence of stimuli, we do not observe any 
inhibition of binding to the CCBD with HP2/1 anti~a4 mAbs, 
whereas these mAbs inhibit binding to CSl (not shown). Thus, 
the reported recognition of RGD by stimulated a4/31 does not 
play a role in our assay. This difference may be explained by 
the fact that Ramos cells, as used by Sanchez-Aparicio et al. 
(34), do not express a5/31. In MV3, the effect of TS2/16 on a4/31
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may be masked by the binding to RGD through a5/31. Alterna­
tively, as previously reported (63), stimulatory j81 mAbs may 
selectively activate a5/31 while leaving a4/31 unaffected.
A possible interpretation of our findings may be that the 
PHSRN synergy site binds to the same epitope as recognized by 
the stimulatory p i  mAbs. It has been previously suggested that 
the epitope where these mAbs bind may physically interact 
with extracellular proteins (55). However, the fact that binding 
of K562 to 3Fn6-10 can be enhanced in the presence of 8A2 or 
TS2/16 when PMA is absent indicates that the synergy site and 
stimulatory mAbs can have additional combined stimulatory 
effects. Therefore, these data seem to support a model where 
the synergy site and stimulatory mAbs have different binding 
sites on a5/31. This is in agreement with the recent report that 
the mechanism of binding of integrin a5/31 to Fn seems to be 
through binding of the a5 subunit to the synergystic regions 
and of the /31 subunit to RGD (64),
In conclusion, our data demonstrate that a5/31 but not avj33 
requires the PHSRN synergy site for cell adhesion to RGD in 
the CCBD of Fn but that induction of a high affinity state of 
a5/31 with PMA, stimulatory mAbs, and/or Mn2+ abrogates 
this dependence on the PHSRN sequence.
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